B
Bull
Bull · 25%BRNS
$2.00
Precio del escenario
$0.765
+0.075 (+9.76%)Al cierre
Loading chart…
- High
- 0.770
- Open
- 0.730
- VWAP
- 0.76
- Vol
- 204.53K
- Mkt Cap
- —
- Low
- 0.730
- Amount
- 154.42K
- EV/EBITDA, TTM
- 0.00
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
AI analysis of Barinthus Biotherapeutics PLC (BRNS)
holdBarinthus Biotherapeutics PLC is currently not a strong buy due to high RSI at 85.243, indicating overbought conditions, and significant recent losses with a 1-year change of -36.38%.
Métricas de valoración
The current forward P/E ratio for Barinthus Biotherapeutics PLC (BRNS) is 0.00, compared to its 5-year average forward P/E of -0.27.
Alphio AI Price Scenarios for BRNS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding BRNS
Cronología de eventos
Noticias
8.508-25NASDAQ.COMBarinthus Biotherapeutics Updates on Merger with Clywedog Therapeutics
8.508-24NewsfilterBarinthus Bio Updates on Merger with Clywedog
8.508-24Yahoo FinanceBarinthus Bio Updates on Merger with Clywedog
7.005-12PRnewswireInvestor Rights Law Firm Investigates Multiple Companies
9.505-01seekingalphaBarinthus Biotherapeutics Reports Q1 Earnings
BRNS FAQ — answered by Alphio AI
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Barinthus Biotherapeutics PLC is currently not a strong buy due to high RSI at 85.243, indicating overbought conditions, and significant recent losses with a 1-year change of -36.38%.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.